<DOC>
	<DOCNO>NCT00427856</DOCNO>
	<brief_summary>Defects apoptotic process lead onset cancer allow cell grow unchecked oncogenic signal present . Obatoclax design restore apoptosis inhibition Bcl-2 family protein , thereby reinstate natural process cell death often inhibited cancer cell .</brief_summary>
	<brief_title>Safety Efficacy Single Agent Obatoclax Mesylate ( GX15-070MS ) Followed Combination With Rituximab Previously-untreated Follicular Lymphoma ( FL )</brief_title>
	<detailed_description>This multi-center , open-label , Phase II study obatoclax administer alone weekly , 3-hour 24-hour infusion 12 week follow combination rituximab patient previously-untreated Follicular Lymphoma . For purpose clinical evaluation , treatment cycle occur 4-week period . Treatment may administer outpatient basis . No investigational commercial agent therapy describe may administer intent treat patient 's malignancy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Pathological confirmation Follicular Lymphoma ( FL ) Must advance stage disease Must receive prior chemotherapy immunotherapy lymphoma , include steroid Must adequate organ function Must ability understand willingness sign write informed consent form No agent therapy administer intent treat malignancy Uncontrolled , intercurrent illness Pregnant woman woman breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>